Circulating microRNA levels predict residual beta cell function and glycaemic control in children with type 1 diabetes mellitus

Diabetologia

Volumn 60, Issue 2, 2017, Pages 354-363

  Samandari, Nasim ^a   Mirza, Aashiq H ^a,b   Nielsen, Lotte B ^a   Kaur, Simranjeet ^a   Hougaard, Philip ^c   Fredheim, Siri ^a   Mortensen, Henrik B ^a,d   Pociot, Flemming ^a,b,d  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Biomarkers; Children; miRNA; Residual beta cell function

Indexed keywords

C PEPTIDE; GONADORELIN RECEPTOR; HEMOGLOBIN A1C; MICRORNA; GLUCOSE BLOOD LEVEL; MIRN146 MICRORNA, HUMAN; MIRN194 MICRORNA, HUMAN; MIRN24 MICRORNA, HUMAN; MIRN375 MICRORNA, HUMAN;

ADOLESCENT; ANGIOGENESIS; ARTICLE; CHILD; CHILDHOOD DISEASE; COHORT ANALYSIS; DISEASE COURSE; FEMALE; GENE TARGETING; GENETIC IDENTIFICATION; GLYCEMIC CONTROL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY CONTROL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; GENETICS; GLUCOSE BLOOD LEVEL; INFANT; METABOLISM; NEWBORN; PRESCHOOL CHILD;

BLOOD GLUCOSE; CHILD, PRESCHOOL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INSULIN-SECRETING CELLS; MALE; MICRORNAS; PROSPECTIVE STUDIES;

EID: 84995810319     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4156-4     Document Type: Article

References (45)

1. Esteller M (2011) Non-coding RNAs in human disease. Nat Rev Genet 12:861–874
2. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell 136:215–233
3. Lai EC (2002) Micro RNAs are complementary to 3′ UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet 30:363–364
4. Guo H, Ingolia NT, Weissman JS, Bartel DP (2010) Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature 466:835–840
5. Rottiers V, Najafi-Shoushtari SH, Kristo F et al (2011) MicroRNAs in metabolism and metabolic diseases. Cold Spring Harb Symp Quant Biol 76:225–233
6. Simpson LJ, Ansel KM (2015) MicroRNA regulation of lymphocyte tolerance and autoimmunity. J Clin Invest 125:2242–2249
7. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO (2007) Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9:654–659
8. Turchinovich A, Weiz L, Langheinz A, Burwinkel B (2011) Characterization of extracellular circulating microRNA. Nucleic Acids Res 39:7223–7233
9. Mathis D, Vence L, Benoist C (2001) beta-Cell death during progression to diabetes. Nature 414:792–798
10. Storling J, Overgaard AJ, Brorsson CA et al (2013) Do post-translational beta cell protein modifications trigger type 1 diabetes? Diabetologia 56:2347–2354
11. Melendez-Ramirez LY, Richards RJ, Cefalu WT (2010) Complications of type 1 diabetes. Endocrinol Metab Clin North Am 39:625–640
12. Collares CV, Evangelista AF, Xavier DJ et al (2013) Identifying common and specific microRNAs expressed in peripheral blood mononuclear cell of type 1, type 2, and gestational diabetes mellitus patients. BMC Res Notes 6:491
13. Nielsen LB, Wang C, Sorensen K et al (2012) Circulating levels of microRNA from children with newly diagnosed type 1 diabetes and healthy controls: evidence that miR-25 associates to residual beta-cell function and glycaemic control during disease progression. Exp Diabetes Res 2012:896362
14. Osmai M, Osmai Y, Bang-Berthelsen CH et al (2016) MicroRNAs as regulators of beta-cell function and dysfunction. Diabetes Metab Res Rev 32:334–349
15. Takahashi P, Xavier DJ, Evangelista AF et al (2014) MicroRNA expression profiling and functional annotation analysis of their targets in patients with type 1 diabetes mellitus. Gene 539:213–223
16. Chen YG, Cabrera SM, Jia S et al (2014) Molecular signatures differentiate immune states in type 1 diabetic families. Diabetes 63:3960–3973
17. Osipova J, Fischer DC, Dangwal S et al (2014) Diabetes-associated microRNAs in pediatric patients with type 1 diabetes mellitus: a cross-sectional cohort study. J Clin Endocrinol Metab 99:E1661–E1665
18. Rajasekar P, O’Neill CL, Eeles L, Stitt AW, Medina RJ (2015) Epigenetic changes in endothelial progenitors as a possible cellular basis for glycemic memory in diabetic vascular complications. J Diabetes Res 2015:436879
19. Santovito D, De Nardis V, Marcantonio P et al (2014) Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control. J Clin Endocrinol Metab 99:E1681–E1685
20. Andersen ML, Rasmussen MA, Porksen S et al (2013) Complex multi-block analysis identifies new immunologic and genetic disease progression patterns associated with the residual beta-cell function 1 year after diagnosis of type 1 diabetes. PLoS One 8, e64632
21. Fredheim S, Andersen ML, Porksen S et al (2015) The influence of glucagon on postprandial hyperglycaemia in children 5 years after onset of type 1 diabetes. Diabetologia 58:828–834
22. Mortensen HB, Hougaard P, Swift P et al (2009) New definition for the partial remission period in children and adolescents with type 1 diabetes. Diabetes Care 32:1384–1390
23. Mortensen HB, Swift PG, Holl RW et al (2010) Multinational study in children and adolescents with newly diagnosed type 1 diabetes: association of age, ketoacidosis, HLA status, and autoantibodies on residual beta-cell function and glycemic control 12 months after diagnosis. Pediatr Diabetes 11:218–226
24. World Health Organization (1999) Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus. Available from http://apps.who.int/iris/handle/10665/66040. Accessed 1 April 2016
25. Blondal T, Jensby Nielsen S, Baker A et al (2013) Assessing sample and miRNA profile quality in serum and plasma or other biofluids. Methods 59:S1–S6
26. Mestdagh P, Van Vlierberghe P, De Weer A et al (2009) A novel and universal method for microRNA RT-qPCR data normalization. Genome Biol 10:R64
27. Hochberg Y (1988) A sharper Bonferroni procedure for multiple tests of significance. Biometrika 75:800–802
28. Dweep H, Sticht C, Pandey P, Gretz N (2011) miRWalk–database: prediction of possible miRNA binding sites by “walking” the genes of three genomes. J Biomed Inform 44:839–847
29. Chou CH, Chang NW, Shrestha S et al (2016) miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res 44:D239–D247
30. Li JH, Liu S, Zhou H, Qu LH, Yang JH (2014) starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res 42:D92–D97
31. Kanehisa M, Goto S (2000) KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic Acids Res 28:27–30
32. Mi H, Muruganujan A, Casagrande JT, Thomas PD (2013) Large-scale gene function analysis with the PANTHER classification system. Nat Protoc 8:1551–1566
33. Zampetaki A, Kiechl S, Drozdov I et al (2010) Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res 107:810–817
34. Khoo C, Yang J, Weinrott SA et al (2012) Research resource: the pdx1 cistrome of pancreatic islets. Mol Endocrinol 26:521–533
35. Kilbride SM, Farrelly AM, Bonner C et al (2010) AMP-activated protein kinase mediates apoptosis in response to bioenergetic stress through activation of the pro-apoptotic Bcl-2 homology domain-3-only protein BMF. J Biol Chem 285:36199–36206
36. Jernas M, Malmestrom C, Axelsson M et al (2013) MicroRNA regulate immune pathways in T cells in multiple sclerosis (MS). BMC Immunol 14:32
37. Magni S, Buoli Comani G, Elli L et al (2014) miRNAs affect the expression of innate and adaptive immunity proteins in celiac disease. Am J Gastroenterol 109:1662–1674
38. Qin Q, Wang X, Yan N et al (2015) Aberrant expression of miRNA and mRNAs in lesioned tissues of Graves’ disease. Cell Physiol Biochem 35:1934–1942
39. Karolina DS, Tavintharan S, Armugam A et al (2012) Circulating miRNA profiles in patients with metabolic syndrome. J Clin Endocrinol Metab 97:E2271–E2276
40. El Ouaamari A, Baroukh N, Martens GA, Lebrun P, Pipeleers D, van Obberghen E (2008) miR-375 targets 3′-phosphoinositide-dependent protein kinase-1 and regulates glucose-induced biological responses in pancreatic beta-cells. Diabetes 57:2708–2717
41. Melkman-Zehavi T, Oren R, Kredo-Russo S et al (2011) miRNAs control insulin content in pancreatic beta-cells via downregulation of transcriptional repressors. EMBO J 30:835–845
42. Nathan G, Kredo-Russo S, Geiger T et al (2015) MiR-375 promotes redifferentiation of adult human beta cells expanded in vitro. PLoS One 10, e0122108
43. Norlin S, Ahlgren U, Edlund H (2005) Nuclear factor-{kappa}B activity in {beta}-cells is required for glucose-stimulated insulin secretion. Diabetes 54:125–132
44. Poy MN, Hausser J, Trajkovski M et al (2009) miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A 106:5813–5818
45. Yu Y, Chai J, Zhang H et al (2014) miR-194 Promotes burn-induced hyperglycemia via attenuating IGF-IR expression. Shock 42:578–584